Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-049 in Combination With Azacitidine and Venetoclax for Newly Diagnosed AML
NCT07722767Phase 1Not yet recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of cln-049 in acute myeloid leukemia (AML) (2 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Incidence and severity of adverse events at 48 weeks and Recommended Phase 2 Dose at 48 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cln-049
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07722767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722767.